Bayer's Dual Track: FDA Nod for Kidney Drug Meets a Farm-Sector Gut Check

FDA accepts Bayer's supplemental filing for Kerendia in non-diabetic kidney disease; shares fell 1.3% to EUR 43.32 as Q3 and legal worries weigh.

Bayer's regulatory machine notched another win this week, but the stock market barely blinked. The FDA has accepted the company's supplemental application for Kerendia (finerenone) in chronic kidney disease patients who do not have diabetes — a filing that, if approved, would stretch the drug's reach well beyond its current type-2 diabetes niche. Shares responded with a 1.3% decline to EUR 43.32 on Thursday, leaving the stock a long way from its 52-week high of EUR 53.86.

The regulatory milestone is not a green light. The FDA's acceptance merely opens the review process; formal approval for the expanded indication remains pending.

What the Filing Rests On

Bayer's submission leans on the Phase III FIND-CKD trial, which enrolled 1,584 adults. As an add-on to standard care, finerenone significantly slowed the annual decline in glomerular filtration rate through month 32. The therapy also cut the relative risk of a composite endpoint combining kidney and cardiovascular complications versus placebo. Serious adverse events tracked comparably with the control arm, though elevated blood potassium appeared somewhat more often on finerenone, as anticipated.

That efficacy package is the prerequisite for winning regulatory recognition of new indications — and for Bayer, the prize is a meaningful expansion of its footprint in cardiology and nephrology.

The commercial math explains the interest. Roughly 850 million people worldwide live with chronic kidney disease, and more than half of them are not diabetic. In the US alone, over 35 million adults have chronic kidney damage, with non-diabetic patients estimated at 50% to 70% of that pool. Kerendia is currently cleared in more than 100 countries, chiefly for adults with kidney disease and type-2 diabetes. A US green light for the new population would widen the drug's therapeutic reach considerably in the world's most lucrative pharmaceutical market.

A Quarter Shadowed by JPMorgan and Missouri

While the pipeline generates headlines, the trading floor is focused on nearer-term pressures. On October 1, JPMorgan analyst Richard Vosser tempered expectations for the third quarter. He kept his "Overweight" rating and EUR 61 price target intact but cautioned that consensus estimates look stretched, pointing to timing effects weighing on the agricultural business. The note triggered visible selling; the stock closed at EUR 43.89 the following day.

Legal matters are compounding the unease. On September 29, a Missouri court began hearing damages claims brought by three women against Monsanto, Bayer's subsidiary. According to Reuters, the case serves as a legal litmus test following the US Supreme Court's landmark ruling, and it centers on allegations of defective product design and inadequate product safety tied to Roundup herbicides.

Those headwinds sit alongside strategic moves. About a week ago, Bayer unveiled a USD 2.2 billion investment in a new production site in New Albany, Ohio, expected to create roughly 600 jobs. Two weeks earlier, the company placed EUR 2 billion in hybrid bonds. Investors are now weighing how much operational drag matters relative to these commitments.

The Farm Question That Decides the Story

The pivotal issue for the share price is whether the agricultural softness reflects pure quarterly phasing or something deeper. Vosser's analysis suggests the timing shifts should barely move full-year estimates — in which case the core business stays on track and investors are simply looking at revenue shifting between reporting periods. If, however, upcoming figures confirm sustained margin pressure in seeds and crop protection, the market will have to re-rate its full-year targets. The Crop Science division's operating result will determine whether Bayer can shore up investor confidence.

Offsetting that risk are pharmaceutical developments that could provide medium-term tailwinds. Bayer strengthened its leadership on October 1, naming Dr. Christoph Koenen as Chief Medical Officer; he now oversees the division's medical and scientific strategy on top of his existing duties. The pipeline also logged recent regulatory wins: the FDA granted Priority Review status to Lynkuet for vasomotor symptoms in hormone receptor-positive breast cancer, while subsidiary BlueRock Therapeutics received Orphan Drug designation for its cell therapy candidate lemiretprocel from both the FDA and the European Medicines Agency.

If Bayer can convert these medical advances into future revenue, the stock has room to run. A robust outlook could pave the way for a re-rating.

Risks That Test Patience

The recovery scenario faces concrete obstacles. The Missouri proceedings make clear that US legal uncertainty is far from resolved; victories for the plaintiffs would spell a continuation of costly glyphosate litigation. At the same time, the capital structure limits financial flexibility — the hybrid bond placement secured liquidity but also underscored ongoing refinancing needs. Should the agricultural business have underperformed in the third quarter, it could meaningfully erode the group's earnings power, and even positive pharma research progress would be drowned out in day-to-day trading.

November 3 Is the Real Verdict

For investors, the coming weeks sharpen the picture. As long as the stock holds above its 200-day moving average of EUR 43.19, the broader recovery pattern stays intact; a slide below that level would cloud the technical signal and invite further selling. The next fixed date is already circled: on November 3, Bayer publishes its official quarterly report for the third quarter of 2026. That day will reveal how heavily the agricultural timing effects actually weighed and whether the annual guidance holds. Until then, signals from the Missouri courtroom and expectations for the business figures are likely to set the stock's direction.